Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pirarubicin + oxaliplatin
- Development stage
- Phase 3
- Lead developer
- Guangxi Medical University
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Pirarubicin + oxaliplatin is a combination chemotherapy regimen being investigated as an adjuvant treatment for hepatocellular carcinoma (HCC) following radical resection. Pirarubicin is a semi-synthetic anthracycline derivative that acts by intercalating into DNA and inhibiting topoisomerase II, thereby preventing DNA replication and RNA synthesis. Oxaliplatin is a third-generation platinum-based antineoplastic agent that forms intra- and inter-strand DNA cross-links, which inhibit DNA synthesis and transcription, leading to apoptosis. This specific combination is being evaluated by Guangxi Medical University in clinical trials to compare its efficacy against transcatheter arterial chemoembolization (TACE) in reducing recurrence and improving survival in HCC patients.
- Other names
- pirarubicin and oxaliplatinTHP + OXAadjuvant systemic chemotherapy (pirarubicin and oxaliplatin)
02
Targets
DNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on pirarubicin + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pirarubicin + oxaliplatin.